Lexicon Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1995-01-01
- Employees
- 285
- Market Cap
- $621.7M
- Website
- http://www.lexpharma.com
- Introduction
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment
Phase 2
Completed
- Conditions
- Age-Related Memory Disorders
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2010-03-03
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 103
- Registration Number
- NCT00691808
- Locations
- 🇳🇱
Kendle Netherlands, Utrecht, Netherlands
🇳🇱Pharmaceutical Research Associates Group BV, Zuidlaren, Netherlands